XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.3
ADDITIONAL BALANCE SHEET DETAIL - Summary of Accrued Expenses and other Current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Product revenue allowances $ 15,361 $ 22,940
Product return reserves, current portion 3,380 5,420
Clinical trial costs 573 328
Compensation and related benefits $ 7,565 $ 8,216
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities
Operating lease liabilities, current portion $ 5,289 $ 4,491
Royalties due to Panion & BF Biotech, Inc. 2,897 3,989
Professional fees 1,130 1,909
Accrued manufacturing costs 645 5,555
Restructuring costs, current portion 762 737
BioVectra, Inc. termination fees, current portion 9,421 7,500
Liability related to sale of future royalties, current portion 2,235 2,048
Other 2,957 4,602
Total accrued expenses and other current liabilities $ 52,215 $ 67,735